Stockreport

Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Cartesian Therapeutics, Inc.  (RNAC) 
PDF Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus ex [Read more]